Aemcolo
- Generic Name: rifamycin delayed-release tablets
- Brand Name: Aemcolo
Aemcolo (Rifamycin Delayed-release Tablets) side effects drug center
Aemcolo Side Effects Center
What Is Aemcolo?
Aemcolo (rifamycin) is a rifamycin antibacterial indicated for the treatment of travelers' diarrhea caused by noninvasive strains of Escherichia coli in adults.
What Are Side Effects of Aemcolo?
Common side effects of Aemcolo include:
- headache,
- constipation,
- abdominal pain,
- fever, and
- indigestion
Dosage for Aemcolo
The recommended dosage of Aemcolo is 388 mg (two tablets) orally twice daily for three days.
What Drugs, Substances, or Supplements Interact with Aemcolo?
Aemcolo may interact with other drugs. Tell your doctor all medications and supplements you use.
Aemcolo During Pregnancy and Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant before using Aemcolo; it is unknown how it would affect a fetus. It is unknown if Aemcolo passes into breast milk. Consult your doctor before breastfeeding.
Additional Information
Our Aemcolo (rifamycin) Delayed-Release Tablets, for Oral Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Aemcolo Consumer Information
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
- severe stomach pain; or
- diarrhea that is watery or bloody.
Common side effects may include:
- constipation; or
- headache.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Aemcolo (Rifamycin Delayed-release Tablets)
Aemcolo Professional Information
SIDE EFFECTS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of oral AEMCOLO 388 mg twice daily was assessed in 619 adults with travelers’ diarrhea in two controlled clinical trials (Trial 1 and Trial 2) with 96% of patients receiving three or four days of treatment. These patients had a mean age of 36.2 years (range 18 to 87 years) with 7% ≥ 65 years old; 49% were male, 84% were White, and 4% were Hispanic.
Discontinuation of AEMCOLO due to adverse reactions occurred in 1% of patients. The most frequent adverse reactions leading to discontinuation of AEMCOLO were abdominal pain (0.5%) and pyrexia (0.3%).
In Trial 1 (placebo-controlled), the adverse reaction that occurred in at least 2% of AEMCOLO-treated patients (n = 199) and with an incidence higher than in the placebo group was constipation (3.5% AEMCOLO, 1.5% placebo)
In Trial 2 (active comparator), the adverse reaction that occurred in at least 2% of AEMCOLO-treated patients (n = 420) and with an incidence higher than in the ciprofloxacin group was headache (3.3% AEMCOLO, 1.9% ciprofloxacin)
Adverse reactions reported in <2% of patients receiving AEMCOLO 388 mg twice daily with a higher incidence than the comparator group was dyspepsia.
Read the entire FDA prescribing information for Aemcolo (Rifamycin Delayed-release Tablets)
&Copy; Aemcolo Patient Information is supplied by Cerner Multum, Inc. and Aemcolo Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.